Key points are not available for this paper at this time.
The 40 μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses. Clinical Trials Registration . NCT03122223.
Share your take
Add a clinician perspective alongside expert commentary.
Chirenje et al. (2023) studied this question.